1. DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies. (25th January 2019) Authors: Chiorean, M; Su, C; Matsuoka, K; Orlando, A; Thorpe, A J; Nduaka, C I; Chapman, D S; Woodworth, D A; Lawendy, N; Friedman, G S; Cohen, R D Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S049 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗